Evidence map›Paper›PMID 35601959›Full record

ArticleComputational and structural biotechnology journal2022

Structural characterization of a cross-protective natural chimera of factor H binding protein from meningococcal serogroup B strain NL096.

Daniele Veggi, Enrico Malito, Paola Lo Surdo, Werner Pansegrau, Valentina Rippa, Newton Wahome, Silvana Savino, Vega Masignani, Mariagrazia Pizza, Matthew J Bottomley

Open access · goldAbstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Daniele VeggiGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Enrico MalitoGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Paola Lo SurdoGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Werner PansegrauGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Valentina RippaGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Newton WahomeGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Silvana SavinoGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Vega MasignaniGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Mariagrazia PizzaGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Matthew J BottomleyGSK Vaccines srl, Via Fiorentina 1, Siena 53100, Italy.
Toscana Life Sciences · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive meningococcal disease can cause fatal sepsis and meningitis and is a global health threat. Factor H binding protein (fHbp) is a protective antigen included in the two currently available vaccines against serogroup B meningococcus (MenB). FHbp is a remarkably variable surface-exposed meningococcal virulence factor with over 1300 different amino acid sequences identified so far. Based on this variability, fHbp has been classified into three variants, two subfamilies or nine modular groups, with low degrees of cross-protective activity. Here, we report the crystal structure of a natural fHbp cross-variant chimera, named variant1-2,3.x expressed by the MenB clinical isolate NL096, at 1.2 Å resolution, the highest resolution of any fHbp structure reported to date. We combined biochemical, site-directed mutagenesis and computational biophysics studies to deeply characterize this rare chimera. We determined the structure to be composed of two adjacent domains deriving from the three variants and determined the molecular basis of its stability, ability to bind Factor H and to adopt the canonical three-dimensional fHbp structure. These studies guided the design of loss-of-function mutations with potential for even greater immunogenicity. Moreover, this study represents a further step in the understanding of the fHbp biological and immunological evolution in nature. The chimeric variant1-2,3.x fHbp protein emerges as an intriguing cross-protective immunogen and suggests that identification of such naturally occurring hybrid proteins may result in stable and cross-protective immunogens when seeking to design and develop vaccines against highly variable pathogens.

Identifiers

PMID35601959
PMCPMC9079162
OpenAlexW4224070292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.